top of page


NeuroTherapia, Inc., was founded in 2015 by Drs. Mohamed Naguib and Joseph Foss with Cleveland Clinic Innovations. It is based on their research on new therapies for diseases with an underlying component of neuroinflammation.  NeuroTherapia became a fully independent company in December, 2019, with the closing of our Series A funding.

Initial research has led to the development of our lead compound, NTRX-07. NTRX-07 (previously known as MDA7) has been shown to decrease the activation of microglial cells in the brain. This effect leads to decreased inflammation and decreased injury to surrounding nerve cells.

Recent work has shown that blocking this inflammation is important in reversing the effects seen in Alzheimer's Disease.

Decreasing this inflammation has also been shown to treat and even prevent the development of neuropathic pain in settings of nerve injury or chemotherapy.

We operate on a virtual model and have assembled a team to develop NTRX-07 as our lead candidate and bring it into clincal use to treat these challenging diseases.

Read more about our team:

bottom of page